Roche's experimental oral drug for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ...

As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a ...

Roche (RHHBY) has received FDA approval for its drug Itovebi in combination with two other drugs for the treatment of breast ...

Brian Roche – when the consultant becomes the bossHaving begun his public sector career as one of those highly paid ...

Novartis' Piqray/Vijoice (alpelisib) is the only PIK3CA inhibitor to have reached the market for breast cancer, having been ...

Skin care aficionados everywhere are making space for a dermatologist-backed, budget-friendly brand in their medicine ...

With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K ...

The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex for certain breast cancer ...

Some trails in the park in central Wisconsin reopened Friday to hikers days after a fire damaged stairway that leads to the ...

Sir Brian Roche has been named as the new public service commissioner, 13 months after Peter Hughes announced his retirement ...

Roche Holding AG will add manufacturing capacity in China to serve the country’s growing market, making it the latest ...

Barclays analyst Emily Field maintained a Hold rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of ...